tradingkey.logo
tradingkey.logo
Search

Insight Molecular Diagnostics Ord Shs

IMDX
Add to Watchlist
2.140USD
-0.170-7.36%
Close 11-13 16:00(ET)
70.02MMarket Cap
LossP/E TTM

About Insight Molecular Diagnostics Ord Shs Company

Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Insight Molecular Diagnostics Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of Insight Molecular Diagnostics Ord Shs

Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Arno
Mr. Andrew (Andy) Arno
Independent Chairman of the Board
Independent Chairman of the Board
117.39K
-10.31%
Mr. Joshua Riggs
Mr. Joshua Riggs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
38.37K
--
Dr. Andrew J. Last
Dr. Andrew J. Last
Independent Director
Independent Director
23.75K
-32.42%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
20.81K
-37.01%
Mr. James Liu, CPA
Mr. James Liu, CPA
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
--
--
Dr. Ekkehard Schuetz, M.D., Ph.D.
Dr. Ekkehard Schuetz, M.D., Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Ms. Andrea S. James
Ms. Andrea S. James
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Arno
Mr. Andrew (Andy) Arno
Independent Chairman of the Board
Independent Chairman of the Board
117.39K
-10.31%
Mr. Joshua Riggs
Mr. Joshua Riggs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
38.37K
--
Dr. Andrew J. Last
Dr. Andrew J. Last
Independent Director
Independent Director
23.75K
-32.42%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
20.81K
-37.01%
Mr. James Liu, CPA
Mr. James Liu, CPA
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
--
--
Dr. Ekkehard Schuetz, M.D., Ph.D.
Dr. Ekkehard Schuetz, M.D., Ph.D.
Chief Science Officer
Chief Science Officer
--
--

FAQs

Who are the top five shareholders of Insight Molecular Diagnostics Ord Shs?

The top five shareholders of Insight Molecular Diagnostics Ord Shs are: Mr. Andrew (Andy) Arno

What is the biggest source of revenue for Insight Molecular Diagnostics Ord Shs?

In 2026Q4, the Pharma Services business generated the highest revenue for Insight Molecular Diagnostics Ord Shs, amounting to 217.49K and accounting for 91.00% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.